Home Minerva Biotechnologies Granted Worldwide License To iPS Technology
 

Keywords :   


Minerva Biotechnologies Granted Worldwide License To iPS Technology

2015-08-05 06:57:21| drugdiscoveryonline Home Page

Minerva Biotechnologies and iPS Academia Japan, Inc. announced recently that they have signed an agreement granting Minerva worldwide rights to use and commercialize the induced Pluripotent Stem (iPS) cells patent portfolio arising from the work of Professor Shinya Yamanaka, MD, Ph.D., who won the Nobel Prize for Medicine in 2012 for his discovery of four genes that can reprogram an adult’s cell to go back in time to become that person’s own stem cell

Tags: technology license worldwide granted

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
03.12Labelexpo South China 2024 features latest industry trends
03.12PPG Earns Two Awards During CARES 2024 Automotive Forums in U.S., Europe
03.12Filtrex 2025 to be Held in March
03.12Nu-Maber Italy adds dual ThermoFlexX Catena-E 80 units
03.12TEKLYNX assists with label compliance
03.12Megnajet supporting Arrow Systems\' growing digital portfolio
03.12WEG Achieves Gold Certification in EcoVadis for Second Consecutive Year
03.12Bank boss takes pay cut after employee 'tried to kill clients'
More »